Hansa Medical has resolved to perform a rights issue of MSEK 246 before issue costs. The new issue of shares is fully underwritten through subscription and guarantee commitments. The funds raised will be used to finance the company’s future research and development activities. In connection herewith, the company also announced that Hansa Medical’s former majority shareholder, Farstorps Gard has sold some of its holding to certain Swedish and international institutional owners.

Hansa Medical is a clinical stage drug development company focused on novel immunomodulatory enzymes. The company’s shares are admitted to trading on Nasdaq First North in Stockholm.

Vinge advised Carnegie which is the financial adviser in conjunction with the capital procurement and sale. The team consisted of partners Peter Bäärnheilm and Dain Nevonen and associate Sabina Börjesson.